A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 744,889 shares of CLSD stock, worth $752,337. This represents 0.0% of its overall portfolio holdings.

Number of Shares
744,889
Previous 582,689 27.84%
Holding current value
$752,337
Previous $757,000 24.97%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.93 - $1.35 $150,846 - $218,970
162,200 Added 27.84%
744,889 $946,000
Q2 2024

Aug 09, 2024

BUY
$1.08 - $1.58 $38,772 - $56,722
35,900 Added 6.57%
582,689 $757,000
Q1 2024

May 13, 2024

BUY
$1.2 - $2.02 $194,520 - $327,442
162,100 Added 42.14%
546,789 $837,000
Q4 2023

Feb 13, 2024

BUY
$0.68 - $1.18 $75,752 - $131,452
111,400 Added 40.76%
384,689 $450,000
Q3 2023

Nov 14, 2023

SELL
$0.82 - $1.27 $51,988 - $80,518
-63,400 Reduced 18.83%
273,289 $238,000
Q2 2023

Aug 11, 2023

SELL
$0.97 - $1.48 $119,019 - $181,596
-122,700 Reduced 26.71%
336,689 $377,000
Q1 2023

May 12, 2023

SELL
$0.93 - $1.66 $119,042 - $212,484
-128,003 Reduced 21.79%
459,389 $478,000
Q4 2022

Feb 13, 2023

SELL
$1.0 - $1.5 $71,097 - $106,645
-71,097 Reduced 10.8%
587,392 $658,000
Q3 2022

Nov 14, 2022

SELL
$1.08 - $1.83 $161,244 - $273,219
-149,300 Reduced 18.48%
658,489 $744,000
Q2 2022

Aug 12, 2022

SELL
$1.3 - $2.49 $74,310 - $142,333
-57,162 Reduced 6.61%
807,789 $1.19 Million
Q1 2022

May 13, 2022

BUY
$1.35 - $2.88 $588,240 - $1.25 Million
435,734 Added 101.52%
864,951 $1.98 Million
Q4 2021

Feb 11, 2022

BUY
$2.72 - $5.72 $891,420 - $1.87 Million
327,728 Added 322.92%
429,217 $1.18 Million
Q3 2021

Nov 12, 2021

BUY
$4.83 - $7.2 $149,247 - $222,480
30,900 Added 43.77%
101,489 $609,000
Q2 2021

Aug 13, 2021

SELL
$2.32 - $5.38 $1.15 Million - $2.66 Million
-493,910 Reduced 87.5%
70,589 $344,000
Q1 2021

May 13, 2021

BUY
$2.24 - $4.25 $235,446 - $446,717
105,110 Added 22.88%
564,499 $1.39 Million
Q4 2020

Feb 10, 2021

SELL
$1.32 - $2.74 $91,872 - $190,704
-69,600 Reduced 13.16%
459,389 $1.26 Million
Q3 2020

Nov 13, 2020

SELL
$1.45 - $2.0 $409,551 - $564,898
-282,449 Reduced 34.81%
528,989 $815,000
Q2 2020

Aug 13, 2020

BUY
$1.55 - $2.41 $648,752 - $1.01 Million
418,550 Added 106.53%
811,438 $1.53 Million
Q1 2020

May 14, 2020

BUY
$1.32 - $3.77 $401,526 - $1.15 Million
304,187 Added 342.94%
392,888 $668,000
Q4 2019

Feb 13, 2020

BUY
$0.62 - $3.4 $54,994 - $301,583
88,701 New
88,701 $257,000
Q2 2019

Aug 12, 2019

SELL
$0.97 - $1.42 $25,915 - $37,938
-26,717 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$1.1 - $1.74 $527,677 - $834,690
-479,707 Reduced 94.72%
26,717 $37,000
Q4 2018

Feb 13, 2019

BUY
$1.0 - $6.12 $506,424 - $3.1 Million
506,424 New
506,424 $542,000

Others Institutions Holding CLSD

About Clearside Biomedical, Inc.


  • Ticker CLSD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,190,700
  • Market Cap $60.8M
  • Description
  • Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...
More about CLSD
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.